PML Nuclear Body Component Sp140 Is a Novel Autoantigen in Primary Biliary Cirrhosis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Some patients with primary biliary cirrhosis (PBC) have antinuclear antibodies (ANAs). These ANAs include the "multiple nuclear dots" (MND) staining pattern, targeting promyelocytic leukemia protein (PML) nuclear body (NB) components, such as "speckled 100-kD" protein (Sp100) and PML. A new PML NB protein, designated as Sp140, was identified using serum from a PBC patient. The aim of this study was to analyze the immune response against Sp140 protein in PBC patients. METHODS: We studied 135 PBC patients and 157 pathological controls with type 1 autoimmune hepatitis, primary sclerosing cholangitis, and systemic lupus erythematosus. We used indirect immunofluorescence and a neuroblastoma cell line expressing Sp140 for detecting anti-Sp140 antibodies, and a commercially available immunoblot for detecting anti-Sp100 and anti-PML antibodies. RESULTS: Anti-Sp140 antibodies were present in 20 (15%) PBC patients but not in control samples, with a higher frequency in antimitochondrial antibody (AMA)-negative cases (53 vs. 9%, P<0.0001). Anti-Sp140 antibodies were found together with anti-Sp100 antibodies in all but one case (19 of 20, 90%) and with anti-PML antibodies in 12 (60%) cases. Anti-Sp140 positivity was not associated with a specific clinical feature of PBC. CONCLUSIONS: Our study identifies Sp140 as a new, highly specific autoantigen in PBC for the first time. The very frequent coexistence of anti-Sp140, anti-Sp100 and anti-PML antibodies suggests that the NB is a multiantigenic complex in PBC and enhances the diagnostic significance of these reactivities, which are particularly useful in AMA-negative cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Gershwin, E. M., Selmi, C., Worman, H. J., Gold, E. B., Watnik, M., Utts, J., Lindor, K. D., Kaplan, M. M., & Vierling, J. M. (2005) · Hepatology · doi:10.1002/hep.20907 · Cited by 621
Vergani, D., Alvarez, F., Bianchi, F. B., Cançado, E. L. R., Mackay, I. R., Manns, M. P., Nishioka, M., & Penner, E. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.08.002 · Cited by 446
Self-citationRisk factors for primary biliary cirrhosis in a cohort of patients from the United States
Parikh-Patel, A., Gold, E. B., Worman, H., Krivy, K. E., & Gershwin, E. M. (2001) · Hepatology · doi:10.1053/jhep.2001.21165 · Cited by 236
Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis
Muratori, P., Muratori, L., Ferrari, R., Cassani, F., Bianchi, G., Lenzi, M., Rodrigo, L., Linares, A., Fuentes, D., & Bianchi, F. B. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07257.x · Cited by 204 · cited 1×
“These findings, as well as their higher frequency in AMA-negative PBC, contribute to enhance the diagnostic potential of anti-NB reactivities, a point of clinical relevance especially when AMAs are absent (”
BackgroundSelf-citationGRANITO, A., MURATORI, P., MURATORI, L., PAPPAS, G., CASSANI, F., WORTHINGTON, J., FERRI, S., QUARNETI, C., CIPRIANO, V., DE MOLO, C., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03433.x · Cited by 102
Self-citationYang, W.-H., Yu, J. H., Nakajima, A., Neuberg, D., Lindor, K., & Bloch, D. B. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00465-3 · Cited by 83
Self-citation
Cited by
Damoiseaux, J., Andrade, L. E. C., Carballo, O. G., Conrad, K., Francescantonio, P. L. C., Fritzler, M. J., Garcia de la Torre, I., Herold, M., Klotz, W., Cruvinel, W. D. M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214436 · Cited by 378
Place your BETs: the therapeutic potential of bromodomains
Prinjha, R. K., Witherington, J., & Lee, K. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.12.002 · Cited by 197
You, H., Ma, X., Efe, C., Wang, G., Jeong, S.-H., Abe, K., Duan, W., Chen, S., Kong, Y., Zhang, D., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10276-6 · Cited by 133
Anti‐kelch‐like 12 and anti‐hexokinase 1: novel autoantibodies in primary biliary cirrhosis
Norman, G. L., Yang, C., Ostendorff, H. P., Shums, Z., Lim, M. J., Wang, J., Awad, A., Hirschfield, G. M., Milkiewicz, P., Bloch, D. B., et al. (2015) · Liver International · doi:10.1111/liv.12690 · Cited by 87
Self-citationZhang, Q., Liu, Z., Wu, S., Duan, W., Chen, S., Ou, X., You, H., Kong, Y., & Jia, J. (2019) · Gastroenterology Research and Practice · doi:10.1155/2019/8959103 · Cited by 28
Metadata
- Authors
- Granito, A., Yang, W.-H., Muratori, L., Lim, M. J., Nakajima, A., Ferri, S., Pappas, G., Quarneti, C., Bianchi, F. B., Bloch, D. B., & Muratori, P.
- Venue
- American Journal of Gastroenterology
- Published
- 2010-01
- Volume
- 105
- Issue
- 1
- Pages
- 125-131
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W1994082232
- Cited by
- 82
- References
- 8
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PML Nuclear Body Component Sp140 Is a Novel Autoantigen in Primary Biliary Cirrhosis. https://app.cochat.ai/papers/10.1038/ajg.2009.596
- The paper
- Granito, A., Yang, W.-H., Muratori, L., Lim, M. J., Nakajima, A., Ferri, S., Pappas, G., Quarneti, C., Bianchi, F. B., Bloch, D. B., & Muratori, P. (2010). PML Nuclear Body Component Sp140 Is a Novel Autoantigen in Primary Biliary Cirrhosis. American Journal of Gastroenterology. https://doi.org/10.1038/ajg.2009.596
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.